NasdaqGM - Nasdaq Real Time Price USD

Rapport Therapeutics, Inc. (RAPP)

25.35 +0.22 (+0.88%)

As of 1:49:04 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 6h ago

RAPP
+0.88%
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

GlobeNewswire 1d ago

RAPP
+0.88%
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

GlobeNewswire 6d ago

RAPP
+0.88%
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

GlobeNewswire 6d ago

RAPP
+0.88%
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

GlobeNewswire 14d ago

RAPP
+0.88%
Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2mo ago

RAPP
+0.88%
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

GlobeNewswire 2mo ago

RAPP
+0.88%
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

GlobeNewswire 2mo ago

RAPP
+0.88%
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

GlobeNewswire 5mo ago

RAPP
+0.88%
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

GlobeNewswire 5mo ago

RAPP
+0.88%
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

GlobeNewswire 6mo ago

RAPP
+0.88%
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

GlobeNewswire 7mo ago

RAPP
+0.88%

Performance Overview

Return	RAPP	S&P 500 (^GSPC)
YTD	-16.45%	+10.80%
1-Year	-5.90%	+10.70%
3-Year	+40.83%	+74.03%

U.S. markets close in 2h 11m

Rapport Therapeutics, Inc. (RAPP)

Trading disclosure

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Performance Overview